Investors were hoping the company would win regulatory approval for its low-cost SurgiBot system, but those hopes were dashed after the U.S. Food and Drug Administration In response, TransEnterix has shifted all of its resources to the launch of itsSenhance Surgery system, which was formerly called the ALF-X. While it is possible that the Senhance system could go on to become a smashing success, here’s a look at three reasons why TransEnterix’s stock could continue to disappoint investors.